Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluating Serum Level Of IL 31 , IL33 and IL36 and Their Correlation with Disease Activity In Patients With Psoriasis In Assuit University Hospital .
Serum samples will be collected from 45 psoriasis patients and 45 matched healthy individuals. After full history taking and dermatological examination, the disease severity will be assessed using the psoriasis area and severity index (PASI) score. All patients enrolled in our study had no other autoimmune or systemic diseases and underwent no systemic treatment including glucocorticoids, immunosuppressive drugs, or phototherapy at least 1 month before the PASI score evaluation and sample collection period. Wriiten informed consent will be obtained from all the patients and healthy controls.
Assessment of serum interleukin-31 ,33 and 36 concentrations in psoriatic patients Patients and controls Blood samples will collected from psoriatic patients and controls, and will centrifuged for 15 min at 1000 rpm. Next, the serum samples will be subdivided into small aliquots to be stored at -80°C until analysis for cytokine levels. ELISA kits will be used to determine serum IL-31 , 33 and 36
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| describe the serum levels of IL31, IL33 and IL36 in egyptian patients with psoriasis. |
| Baseline |
| 4. Knowing the extent of disease activity by Psoriasis Area and Severity Index (PASI) score. | assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease). | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| serum level of interleukins reflect severity of disease and represent anovel target for antipsoriatic drug theraby. | increase of the serum level of interleukins during disease activity means significant increase which has a value in drug therapy of psoriasis . and vice versa. | Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
study will be performed on 45 psoriasis patients and 45 healthy matched volunteers without a family history of psoriasis and other autoimmune as well as inflammatory diseases and underwent no systemic treatment including glucocorticoids, immunosuppressive drugs, or phototherapy at least 1 month before the PASI score ,evaluation and sample collection period . All patients will be recruited from the Psoriasis Clinic in Dermatology Department of Assuit University Hospital
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided